omp-52m51
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT01703572)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
NOTCH1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- brontictuzumab
- brontictuzumab
- omp-52m51
- omp-52m51
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03031691 | Phase 1 | Jan 1, 2017 | Mereo BioPharma |
| NCT02662608 | N/A | Dec 29, 2015 | University of Texas at Houston |
| NCT01778439 | Phase 1 | Feb 1, 2013 | Mereo BioPharma |
| NCT01703572 | Phase 1 | Oct 1, 2012 | Mereo BioPharma |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mereo BioPharma | For profit | 3 | 3 | 1 | 2012 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1